NCT00546377View on ClinicalTrials.gov

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

filgrastim

BIOLOGICAL

pegfilgrastim

BIOLOGICAL

rituximab

BIOLOGICAL

sargramostim

DRUG

cyclophosphamide

DRUG

mitoxantrone hydrochloride

DRUG

pentostatin

GENETIC

fluorescence in situ hybridization

GENETIC

gene rearrangement analysis

GENETIC

polymerase chain reaction

GENETIC

protein expression analysis

OTHER

flow cytometry

PROCEDURE

biopsy

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00546377 - Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | Biotech Hunter | Biotech Hunter